Diaverum, a leading global renal care service provider, is proud to announce that its Saudi Arabia operation has been accredited for the first time by the Joint Commission International (JCI) for its ambulatory care network. The world-renowned accreditation demonstrates the company’s excellence in renal care provision and organisation management in the country.
The JCI and its quality mark, Gold Seal of Approval®, have for more than 45 years formed a globally recognised benchmark that represents one of the most comprehensive evaluation processes in the healthcare industry. Its Ambulatory Care Accreditation Programme sets the standard and offers recognition to safe, high-quality patient care practices across a spectrum of freestanding ambulatory care facilities worldwide.
This accreditation is testament to the standards of excellence Diaverum has achieved since it began offering life enhancing care to patients with End-Stage Renal Disease (ESRD) in Saudi Arabia over eight years ago. The implementation of Diaverum’s integrated, patient-centric model, that delivers benchmark medical outcomes and patient satisfaction levels, both within the company’s global network of clinics as well as industry-wide, has been integral to meeting the JCI’s standards of performance.
Commenting on the significance of the JCI accreditation, Ziyad Kabli, Country Manager for Saudi Arabia and Regional Vice President for the Middle East region, said: “We receive the JCI accreditation with great pride. It’s a true testament to our one-of-a-kind, value-based care delivery approach that has been providing superior medical outcomes to our patients. Our vision at Diaverum is to transform renal services, empowering our patients to live fulfilling lives. This means we set the bar high, putting the patient first and very often, going beyond contractual requirements to offer the highest quality of care.”
Ali Shakir, Business Development Director at Diaverum, added that: “The world renowned JCI accreditation for ambulatory care networks enhances the sustainability of our Public Private Partnership (PPP) with the Ministry of Health of Saudi Arabia; enabling access to quality care across the Kingdom since 2013. This accreditation advocates for further developing healthcare models based on values and outcomes. This will inevitably strengthen our market position in the region as the renal care provider of choice for patients, national health services and healthcare professionals alike”.
Since Diaverum commenced operations in Saudi Arabia in 2013, it has made significant investments in its clinic infrastructure. It has also transferred medical and operational knowledge to develop both local and international talents through Diaverum’s d.ACADEMY programme, which in Saudi Arabia comprises a certified training centre located in Riyadh, providing continuous education in practice through physical and virtual training modules, with accreditation from the Saudi Commission for Health Specialties (SCFHS).
Nationwide, Diaverum Saudi Arabia provides holistic dialysis services, including among others the coordination of patients’ comorbidities through nutrition, pharmaceutical and social care, as well as vascular access surgeries and holiday dialysis.
Today, Diaverum provides care for more than 4,300 patients across 40 clinics in 33 cities and towns, making it the largest renal care provider in Saudi Arabia and the Middle East.
© Press Release 2021
Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.
The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.
To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.
